Exeltis, a branch of the pharmaceutical Grupo Chemo, has acquired 100% of the Turkish pharmaceutical Embil.The deal is the biggest acquisition ever by Exeltis abroad.It also represents the entry of the Spanish company into Turkey, a market of great potential due to its population and its high proportion of young people (nearly a third are under 15 years of age).
The deal is part of Exeltis's Strategic Plan that aims to consolidate its international development. Following its acquisitions in India, Indonesia and the United States, the company already has a presence in more than 40 countries, thanks to 30 subsidiaries in key markets and its extensive global manufacturing network in Europe, America and Asia.
With a presence in over 40 countries, Exeltis continues to forge ahead from one country to the next in its aim to reach all corners of the world while providing therapeutic solutions to millions of people. In Asia, we are already in China, the Philippines, Malaysia, Singapore, India, Indonesia and Thailand, and we are now able to add Exeltis Vietnam to that list.
Quinnova Pharmaceuticals LLC, an affiliate of Exeltis™, today announced the launch of its recently U.S. Food and Drug Administration approved ECOZA™ (econazole nitrate) topical foam, 1%. ECOZA™ FOAM is indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older.